SCHEMBL16615260

SCHEMBL16615260

O=C(CN1CCCC1)c1cc2c(nn1)NCCN2Cc1cc(Cl)ccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 11/20 0.45
DRD2 P14416 2/20 0.37
DRD4 P21917 1/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
ATM Q13315 1/20 0.36
DRD3 P35462 1/20 0.35
KCNH2 Q12809 1/20 0.35
CHEK1 O14757 1/20 0.35
AURKA O14965 1/20 0.35
JAK2 O60674 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
ABL1 P00519 1/20 0.35
NTRK1 P04629 1/20 0.35
LCK P06239 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
IGF1R P08069 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615157 0.86 ALK (0.51) ALK
SCHEMBL17918668 0.79 ALK (0.53) ALKDRD2MAPTDRD3KCNH2
SCHEMBL16615211 0.79 ALK (0.53) ALKALDH1A1MAPTMETMAP4K2
SCHEMBL17918715 0.78 KCNQ2 (0.44) ALKALDH1A1MAPTATM
SCHEMBL17918855 0.76 ALK (0.59) ALKMAPTCHEK1AURKAJAK2
SCHEMBL17918706 0.75 MAPT (0.44) ALKALDH1A1MAPTLMNAATM
SCHEMBL18106061 0.75 ALK (0.45) ALKALDH1A1MAPTLMNAATM
SCHEMBL17918724 0.75 CCNC (0.47) ALKMAPTMETFLT3MAP4K2
SCHEMBL18106054 0.75 ALK (0.53) ALKMAPTATMCHEK1AURKA
SCHEMBL16615184 0.74 ALK (0.46) ALKCHEK1AURKAJAK2PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3050884-B1 NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES LIMITED LIABILITY COMPANY NATIONAL PHARMACEUTICAL TECH (RU) 2019-04-03 EP disclosed
US-9695182-B2 Chemical compounds (derivatives) and their application for the treatment of oncological diseases LIMITED LIABILITY COMPANY “NATIONAL PHARMACEUTICAL TECHNOLOGIES” (RU) 2017-07-04 US disclosed
EP-3050884-A1 NOVEL CHEMICAL COMPOUNDS (VARIANTS) AND THE USE THEREOF TO TREAT ONCOLOGICAL DISEASES Limited Liability Company "National Pharmaceutical (RU) 2016-08-03 EP disclosed
US-20160200729-A1 NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES LIMITED LIABILITY COMPANY (RU) 2016-07-14 US disclosed
WO-2015047133-A1 NOVEL CHEMICAL COMPOUNDS (VARIANTS) AND THE USE THEREOF TO TREAT ONCOLOGICAL DISEASES ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ОТЕЧЕСТВЕННЫЕ ФАРМАЦЕВТИЧЕСКИЕ ТЕХНОЛОГИИ" 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200729-A1 NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES BRAF, CNKSR1, RAF1 ALK 1031/4885DRD2 4583/4885DRD4 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.